The phase I trial evaluated CAR T cells targeting CD19, CD20, and CD22 in patients with relapsed or refractory B-cell malignancies.
2
Point-of-care manufacturing produced CAR T cells in a median of 7 days, with successful production for 16 of 17 patients.
3
Among 16 treated patients, the overall response rate was 50%, and 38% achieved complete responses.
4
Five of 6 patients with B-cell non-Hodgkin lymphoma achieved complete remission, and 4 remained in remission beyond 1 year.
5
No severe cytokine release syndrome, dose-limiting toxicities, or immune effector cell-associated neurotoxicity syndrome occurred; pretreatment T-cell exhaustion markers were higher in patients whose
